Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic pancreatic islet cells are a biologic cell therapy consisting of purified clusters of endocrine cells (islets of Langerhans) derived from a donor pancreas. In the context of the ITA-OMEN trial led by Lorenzo Piemonti at Ospedale San Raffaele, these cells are being investigated for transplantation into the omentum as an alternative to the standard intrahepatic portal vein delivery. The primary goal is to restore endogenous insulin production and glycemic control in patients with type 1 diabetes mellitus who experience severe hypoglycemic unawareness or metabolic instability. The procedure requires a concomitant immunosuppressive regimen to prevent graft rejection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allogeneic pancreatic islet cells.